Abstract
Liver cirrhosis is a leading cause of mortality worldwide. Although treatable by liver transplantation, quality of life is unlikely to drop in all the patients after five years. The shortage of matching donors and the high risk of surgical-associated complications further limits the therapeutic potential of transplantation.
Highlights
Liver cirrhosis is an end-stage pathological condition that results from a range of chronic liver diseases
Since adult stem cells can be effectively differentiated into hepatocyte-like cells, the potential to translate this utility as a therapeutic alternative has been considerably explored
The bone marrow serves as an ideal source of Hematopoietic Stem Cells (HSCs) and Mesenchymal Stem Cells (MSCs)
Summary
Liver cirrhosis is an end-stage pathological condition that results from a range of chronic liver diseases. The application of multipotent adult stem cells has been identified as being safe with no significant ethical constraints Various obstacles such as limited knowledge in stem cell biology, insufficient cell number and technological challenges surrounding in vitro expansion that previously hampered the utility of these cells have been supplanted in recent years. Numerous clinical studies have demonstrated that the use of bone marrow-derived stem cells is safe and results in significant improvement in minimizing disease progression. Autologous bone marrow-derived stem cells have been used to treat end-stage liver failure or cirrhosis [20,21,22]. Due to their unique self-renewal and multi-differentiation potential, HSCs were thought to have the most regenerative potential.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
